Fridman W.H.Petitprez F.Meylan M.WEI-WU CHENSun C.-M.Roumenina L.T.Saut?s-Fridman C.2022-03-152022-03-1520210022-1007https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101021080&doi=10.1084%2fJEM.20200851&partnerID=40&md5=c15d03b0fffcf1f1f281cdff987654ebhttps://scholars.lib.ntu.edu.tw/handle/123456789/597532Whereas T cells have been considered the major immune cells of the tumor microenvironment able to induce tumor regression and control cancer clinical outcome, a burst of recent publications pointed to the fact that B cells may also play a prominent role. Activated in germinal centers of tertiary lymphoid structures, B cells can directly present tumor-associated antigens to T cells or produce antibodies that increase antigen presentation to T cells or kill tumor cells, resulting in a beneficial clinical impact. Immune complexes can also increase inflammation, angiogenesis, and immunosuppression via macrophage and complement activation, resulting in deleterious impact. ? 2020 Fridman et al.[SDGs]SDG3tumor antigen; angiogenesis; B lymphocyte; complement activation; germinal center; human; immunosuppressive treatment; inflammation; macrophage; malignant neoplasm; nonhuman; priority journal; Review; T lymphocyte; tertiary lymphoid structure; tumor immunology; animal; B lymphocyte; immunology; neoplasm; neovascularization (pathology); pathology; tumor microenvironment; vascularization; Animals; Antigens, Neoplasm; B-Lymphocytes; Complement Activation; Humans; Inflammation; Macrophages; Neoplasms; Neovascularization, Pathologic; T-Lymphocytes; Tumor Microenvironmentreview10.1084/JEM.20200851336014132-s2.0-85101021080